[go: up one dir, main page]

RU2003118436A - ANKARA MODIFIED VERSION OF ANKARA - Google Patents

ANKARA MODIFIED VERSION OF ANKARA

Info

Publication number
RU2003118436A
RU2003118436A RU2003118436/13A RU2003118436A RU2003118436A RU 2003118436 A RU2003118436 A RU 2003118436A RU 2003118436/13 A RU2003118436/13 A RU 2003118436/13A RU 2003118436 A RU2003118436 A RU 2003118436A RU 2003118436 A RU2003118436 A RU 2003118436A
Authority
RU
Russia
Prior art keywords
virus
paragraphs
inoculation
vaccine
genome
Prior art date
Application number
RU2003118436/13A
Other languages
Russian (ru)
Other versions
RU2290438C2 (en
Inventor
Пол Чаплин
Пол Хаули
Кристине МАЙЗИНГЕР
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of RU2003118436A publication Critical patent/RU2003118436A/en
Application granted granted Critical
Publication of RU2290438C2 publication Critical patent/RU2290438C2/en

Links

Claims (27)

1. Вирус коровьей оспы, имеющий, по меньшей мере, одно из следующих свойств:1. The vaccinia virus, having at least one of the following properties: (i) способность к репродукции путем репликации в фибробластах эмбрионов цыплят (CEF) и в линии клеток почек детенышей хомячка BHK, но отсутствие способности к репродукции путем репликации в клеточной линии кератиноцитов человека HaCat,(i) the ability to reproduce by replication in fibroblasts of chicken embryos (CEF) and in the cell line of the kidney cells of young BHK hamster, but the lack of ability to reproduce by replication in the cell line of human keratinocytes HaCat, (ii) отсутствие способности к репликации in vivo,(ii) lack of in vivo replication ability, (iii) индукция более сильного иммунитета по сравнению с известным штаммом MVA 575 в модели летального заражения и/или(iii) the induction of stronger immunity compared to the known strain MVA 575 in the model of lethal infection and / or (iv) индукция, по меньшей мере, по существу того же самого уровня иммунитета при режимах первичной иммунизации вирусом коровьей оспы/повторной иммунизации вирусом коровьей оспы по сравнению с режимами первичной иммунизации ДНК/повторной иммунизации вирусом коровьей оспы.(iv) the induction of at least substantially the same level of immunity in the primary vaccination with vaccinia virus / reimmunization with vaccinia virus compared with the primary immunization with DNA / reimmunization with vaccinia virus. 2. Вирус по п. 1, где вирус не способен к репродукции путем репликации в любой из следующих клеточных линий человека: линии клеток почки эмбриона человека 293, клеточной линии остеосаркомы кости человека 143B и клеточной линии аденокарциномы шейки матки человека HeLa.2. The virus of claim 1, wherein the virus is not capable of reproduction by replication to any of the following human cell lines: human embryonic kidney cell line 293, human bone osteosarcoma cell line 143B, and human cervical adenocarcinoma cell line HeLa. 3. Вирус по п. 1 или 2, положенный на хранение в Европейскую коллекцию клеточных культур (ECACC) Salisbury (UK) под номером V00083008, и его производные.3. The virus according to claim 1 or 2, deposited in the European collection of cell cultures (ECACC) Salisbury (UK) under the number V00083008, and its derivatives. 4. Вирус по любому из пп. 1-3, включающий, по меньшей мере, одну последовательность гетерологичной нуклеиновой кислоты.4. The virus according to any one of paragraphs. 1-3, comprising at least one heterologous nucleic acid sequence. 5. Вирус по п. 4, где указанная последовательность гетерологичной нуклеиновой кислоты выбрана из последовательности, кодирующей, по меньшей мере, один антиген, антигенный эпитоп и/или терапевтическое соединение.5. The virus of claim 4, wherein said heterologous nucleic acid sequence is selected from a sequence encoding at least one antigen, antigenic epitope and / or therapeutic compound. 6. Геном или его функциональные части, происходящие от вируса по любому из пп. 1-5.6. The genome or its functional parts originating from the virus according to any one of paragraphs. 1-5. 7. Фармацевтическая композиция, включающая вирус по любому из пп. 1-5, и/или геном, и/или его функциональную часть по п. 6, и фармацевтически приемлемый носитель, разбавитель и/или добавку.7. A pharmaceutical composition comprising a virus according to any one of paragraphs. 1-5, and / or the genome, and / or its functional part according to claim 6, and a pharmaceutically acceptable carrier, diluent and / or additive. 8. Вакцина, включающая вирус, по любому из пп. 1-5, и/или геном, и/или его функциональную часть по п. 6.8. The vaccine comprising the virus, according to any one of paragraphs. 1-5, and / or the genome, and / or its functional part according to claim 6. 9. Вирус по любому из пп. 1-5, геном и/или его функциональная часть по п. 6, композиция по п. 7, или вакцина по п. 8, в качестве лекарства для влияния на иммунный ответ, предпочтительно для его индукции, у живого животного, включая человека.9. The virus according to any one of paragraphs. 1-5, the genome and / or its functional part according to claim 6, the composition according to claim 7, or the vaccine according to claim 8, as a medicine for influencing the immune response, preferably for its induction, in a living animal, including humans. 10. Вирус по любому из пп. 1-5, фармацевтическая композиция по п. 7, вакцина по п. 8, или вирус по п. 9, где вирус, композицию или вакцину вводят в терапевтически эффективных количествах при первой инокуляции (“примирующая инокуляция”) и при второй инокуляции (“бустерная инокуляция”).10. The virus according to any one of paragraphs. 1-5, the pharmaceutical composition according to claim 7, the vaccine according to claim 8, or the virus according to claim 9, wherein the virus, composition or vaccine is administered in therapeutically effective amounts during the first inoculation (“priming inoculation”) and during the second inoculation (“ booster inoculation ”). 11. Применение вируса по любому из пп. 1-5, и/или генома по п.6, для получения лекарства или вакцины.11. The use of the virus according to any one of paragraphs. 1-5, and / or genome according to claim 6, to obtain a medicine or vaccine. 12. Способ введения гомологичной и/или гетерологичной последовательности нуклеиновой кислоты в клетки-мишени, включающий инфицирование клеток-мишеней вирусом по п. 4 или 5, или трансфекцию клетки-мишени геномом по п. 6.12. A method for introducing a homologous and / or heterologous nucleic acid sequence into target cells, comprising infecting the target cells with a virus according to claim 4 or 5, or transfecting the target cell with a genome according to claim 6. 13. Способ получения пептида, белка и/или вируса, включающий13. A method of producing a peptide, protein and / or virus, comprising a) инфицирование клетки-хозяина вирусом по п. 1 или 5,a) infection of the host cell with a virus according to claim 1 or 5, b) культивирование инфицированной клетки-хозяина в подходящих условиях иb) culturing the infected host cell under suitable conditions and c) выделение и/или повышение концентрации пептида, и/или белка, и/или вирусов, продуцируемых указанной клеткой-хозяином.c) isolating and / or increasing the concentration of the peptide and / or protein and / or viruses produced by said host cell. 14. Способ влияния на иммунный ответ, предпочтительно его индукцию, в организме живого животного, включая человека, включающий введение вируса, по любому из пп. 1-5, генома и/или его функциональной части по п.6, композиции по п. 7, или вакцины по п. 8, животному или человеку, подвергаемому лечению.14. The method of influencing the immune response, preferably its induction, in the body of a living animal, including humans, including the introduction of the virus, according to any one of paragraphs. 1-5, the genome and / or its functional part according to claim 6, the composition according to claim 7, or the vaccine according to claim 8, to an animal or person being treated. 15. Способ по п. 14, включающий введение, по меньшей мере, 102 TCID50 (дозы инфицирования в тканевой культуре) вируса.15. The method according to p. 14, comprising the introduction of at least 10 2 TCID 50 (dose of infection in tissue culture) of the virus. 16. Способ по п. 14 или 15, в котором вирус, композицию или вакцину вводят в терапевтически эффективных количествах при первой инокуляции (“примирующая инокуляция”) и при второй инокуляции (“бустерная инокуляция”).16. The method according to p. 14 or 15, in which the virus, composition or vaccine is administered in therapeutically effective amounts during the first inoculation (“priming inoculation”) and during the second inoculation (“booster inoculation”). 17. Способ по любому из пп. 14-16, где животное имеет нарушенный иммунитет.17. The method according to any one of paragraphs. 14-16, where the animal has impaired immunity. 18. Способ по любому из пп. 14-17, где животное имеет уже существующий иммунитет по отношению к вирусам оспы.18. The method according to any one of paragraphs. 14-17, where the animal has a pre-existing immunity against smallpox viruses. 19. Способ по любому из пп. 14-18, где животное подвергается противовирусной терапии.19. The method according to any one of paragraphs. 14-18, where the animal undergoes antiviral therapy. 20. Способ по п. 19, где противовирусная терапия представляет собой терапию против ретровирусов.20. The method according to p. 19, where the antiviral therapy is a therapy against retroviruses. 21. Применение вируса по любому из пп. 1-5, генома и/или его функциональной части по п. 6, в качестве адъюванта.21. The use of the virus according to any one of paragraphs. 1-5, the genome and / or its functional part according to claim 6, as an adjuvant. 22. Способ увеличения специфического иммунного ответа против антигена и/или антигенного эпитопа, включенного в вакцину, включающий введение в качестве адъюванта вируса по любому из пп. 1-5, или генома по п. 6, в организм живого животного, включая человека, подвергаемого лечению вакциной.22. A method of increasing a specific immune response against an antigen and / or antigenic epitope included in a vaccine, comprising administering as a adjuvant the virus according to any one of claims. 1-5, or the genome of claim 6, into the body of a living animal, including the person being treated with the vaccine. 23. Вирус, по любому из пп. 1-5, или геном по п. 6, в качестве адъюванта.23. The virus, according to any one of paragraphs. 1-5, or the genome according to claim 6, as an adjuvant. 24. Клетка, предпочтительно клетка человека, содержащая вирус по любому из пп. 1-5, или геном, или его функциональную часть по п. 6.24. A cell, preferably a human cell, containing the virus according to any one of claims. 1-5, or the genome, or its functional part according to claim 6. 25. Способ получения вируса коровьей оспы, по любому из пп. 1-3, включающий следующие стадии:25. The method of obtaining the vaccinia virus, according to any one of paragraphs. 1-3, including the following stages: - введение обычного доступного штамма вируса коровьей оспы, предпочтительно MVA 575 в клетки, отличные от клеток человека, в которых вирус способен к репродукции путем репликации, где клетки, отличные от клеток человека, предпочтительно выбраны из клеток CEF и клеточной линии BHK,- introducing the usual available strain of vaccinia virus, preferably MVA 575, into cells other than human cells, in which the virus is capable of reproduction by replication, where cells other than human cells are preferably selected from CEF cells and the BHK cell line, - выделение/увеличение концентрации вирусных частиц из данных клеток и- isolation / increase in the concentration of viral particles from these cells and - анализ того, будет ли полученный вирус иметь, по меньшей мере, одно из биологических свойств, как указано в п. 1,- analysis of whether the resulting virus will have at least one of the biological properties, as described in paragraph 1, где указанные выше стадии могут необязательно повторяться до тех пор, пока не будет получен вирус с желаемыми репликативными характеристиками.where the above steps may optionally be repeated until a virus with the desired replicative characteristics is obtained. 26. Набор для примирующей/бустерной иммунизации, включающий вирус по любому из пп. 1-5, композицию по п. 7, вакцину по п.8, или вирус по п. 9, для первой инокуляции (“примирующая инокуляция”) в первом флаконе/контейнере и для второй инокуляции (“бустерная инокуляция”) во втором флаконе/контейнере.26. A kit for priming / booster immunization, comprising the virus according to any one of paragraphs. 1-5, the composition of claim 7, the vaccine of claim 8, or the virus of claim 9, for the first inoculation (“reconciliation inoculation”) in the first vial / container and for the second inoculation (“booster inoculation”) in the second vial / container. 27. Применение вируса по любому из пп. 1-5, композиции по п. 7, вакцины по п. 8 или вируса по п. 9 для получения вакцины, где вирус, композицию или вакцину вводят в терапевтически эффективных количествах при первой инокуляции и при второй инокуляции.27. The use of the virus according to any one of paragraphs. 1-5, the composition according to p. 7, the vaccine according to p. 8 or the virus according to p. 9 to obtain a vaccine, where the virus, composition or vaccine is administered in therapeutically effective amounts during the first inoculation and the second inoculation.
RU2003118436/13A 2000-11-23 2001-11-22 Modified variant of ankara vaccina virus RU2290438C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001764 2000-11-23
DKPA200001764 2000-11-23

Publications (2)

Publication Number Publication Date
RU2003118436A true RU2003118436A (en) 2004-12-27
RU2290438C2 RU2290438C2 (en) 2006-12-27

Family

ID=8159864

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003118436/13A RU2290438C2 (en) 2000-11-23 2001-11-22 Modified variant of ankara vaccina virus

Country Status (29)

Country Link
US (11) US6913752B2 (en)
EP (4) EP2202315A1 (en)
JP (1) JP4421188B2 (en)
KR (3) KR100830295B1 (en)
CN (2) CN100537773C (en)
AT (1) ATE314483T2 (en)
AU (2) AU3163902A (en)
BE (1) BE2013C065I2 (en)
BR (1) BRPI0115533B8 (en)
CA (1) CA2421151C (en)
CY (2) CY1105594T1 (en)
CZ (1) CZ295808B6 (en)
DE (2) DE60116371T3 (en)
DK (1) DK1335987T4 (en)
EE (1) EE05680B1 (en)
ES (1) ES2256323T5 (en)
FR (1) FR13C0070I2 (en)
HU (2) HU230198B1 (en)
IL (2) IL154712A0 (en)
LU (1) LU92311I2 (en)
MX (1) MXPA03002513A (en)
NO (1) NO337867B1 (en)
NZ (1) NZ524661A (en)
PL (1) PL212047B1 (en)
PT (1) PT1335987E (en)
RU (1) RU2290438C2 (en)
SI (1) SI1335987T2 (en)
UA (1) UA76731C2 (en)
WO (1) WO2002042480A2 (en)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
AU3163902A (en) † 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA82466C2 (en) * 2001-07-18 2008-04-25 Бавариан Нордика А/С Method for intensification of chordopoxvirus amplification
CN101397574A (en) 2001-12-04 2009-04-01 巴法里安诺迪克有限公司 Flavivirus NS1 subunit vaccine
JP4801880B2 (en) 2002-04-19 2011-10-26 バヴァリアン・ノルディック・アクティーゼルスカブ Mutant vaccinia virus Ankara for newborn immunization
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
KR101138067B1 (en) 2002-05-16 2012-04-24 버베리안 노딕 에이/에스 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
BR0310020A (en) * 2002-05-16 2005-02-15 Bavarian Nordic As Expression of genes in modified vaccinia virus ankara by use of vaccinia ati promoter
KR101044538B1 (en) 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 Primary cell culture and virus propagation under serum-free conditions
DE602004009743T2 (en) * 2003-11-24 2008-08-28 Bavarian Nordic A/S Promoters for expression in modified vaccinia virus Ankara
US20080102524A1 (en) * 2004-06-14 2008-05-01 Ishihara Sangyo Kaisha, Ltd. Freeze-Dried Composition of Inactivated Virus Envelope with Membrane Fusion Activity
CN1295339C (en) * 2005-01-11 2007-01-17 武汉大学 Attenuated vaccinia virus Tiantan strain vector and its preparation and application
WO2006089690A1 (en) 2005-02-23 2006-08-31 Bavarian Nordic A/S Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
WO2006113927A2 (en) * 2005-04-20 2006-10-26 University Of Washington Immunogenic vaccinia peptides and methods of using same
KR100717279B1 (en) * 2005-08-08 2007-05-15 삼성전자주식회사 Mask ROM Device and Formation Method
US7913477B2 (en) * 2006-01-27 2011-03-29 William Anthony Harper Insert registration in packets
EP1826264A1 (en) * 2006-02-24 2007-08-29 Deutsches Primatenzentrum GmbH Primate model for orthopox virus infections
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
RU2453335C2 (en) 2006-06-20 2012-06-20 Трансжене С.А. Recombinant viral vaccine
EP2530161B1 (en) * 2006-06-20 2018-03-28 Transgene SA Process for producing poxviruses and poxvirus compositions
EP2064351A1 (en) * 2006-09-08 2009-06-03 Bavarian Nordic A/S Phenotypic and genotypic differences of mva strains
US7807146B2 (en) * 2006-10-06 2010-10-05 Bn Immunotherapeutics, Inc. Methods for treating cancer with a recombinant MVA expressing HER-2
US8268327B2 (en) * 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
AU2008250596C1 (en) 2007-05-14 2010-11-25 Bavarian Nordic A/S Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines
ES2608604T3 (en) * 2007-10-18 2017-04-12 Bavarian Nordic A/S Use of MVA to treat prostate cancer
KR100970449B1 (en) * 2007-12-21 2010-07-16 (주)이지아이 Rubber flooring and installation method for children's playground with safety
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
JP5379243B2 (en) 2009-01-20 2013-12-25 トランジェーヌ、ソシエテ、アノニム Biomarkers and related methods for selecting patients
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
JP5774578B2 (en) 2009-03-24 2015-09-09 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． Biomarkers for monitoring patients
HRP20140262T1 (en) 2009-04-17 2014-04-25 Transgene Sa Biomarker for monitoring patients
JP5650212B2 (en) 2009-07-10 2015-01-07 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． Biomarkers and related methods for selecting patients
AU2010305030A1 (en) 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
WO2011063359A1 (en) * 2009-11-20 2011-05-26 Inviragen, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs
DK2529010T3 (en) 2010-01-28 2017-07-24 Bavarian Nordic As MUTANTS OF VACCINIAVIRUS CONTAINING THE MAIN GENOMIC DELETIONS OF VAT
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
CA2802430C (en) 2010-07-20 2021-07-20 Bavarian Nordic A/S Method for harvesting poxvirus
WO2012018856A2 (en) * 2010-08-02 2012-02-09 Virxsys Corporation Hiv vaccine therapy with concomitant antiviral monotherapy
EP2627774B1 (en) 2010-10-15 2018-11-21 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) influenza vaccine
PL2691530T3 (en) 2011-06-10 2019-02-28 Oregon Health & Science University Glycoproteins and recombinant CMV vectors
KR102022952B1 (en) * 2011-08-05 2019-09-20 신라젠(주) Methods and compositions for production of vaccina virus
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2013189611A1 (en) 2012-06-22 2013-12-27 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
MX366206B (en) 2012-07-10 2019-07-02 Transgene Sa Mycobacterial antigen vaccine.
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
EP2879702B9 (en) 2012-08-01 2020-02-26 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
EP3639851A1 (en) 2012-09-04 2020-04-22 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
AU2013331328B2 (en) 2012-10-19 2018-05-31 Bavarian Nordic A/S Methods and compositions for the treatment of cancer
BR112015009320A2 (en) 2012-10-28 2017-10-17 Bavarian Nordic As pr13.5 promoter for robust t-cell and antibody responses
MY175269A (en) * 2013-03-15 2020-06-17 Bavarian Nordic As Single high dose of mva induces a protective immune response in neonates and infants
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3060232B1 (en) 2013-10-23 2018-07-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015078856A1 (en) 2013-11-28 2015-06-04 Bavarian Nordic A/S Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
KR20160130216A (en) 2014-01-09 2016-11-10 트랜스진 에스아이 Fusion of heterooligomeric mycobacterial antigens
JP2017515841A (en) 2014-05-13 2017-06-15 バヴァリアン・ノルディック・アクティーゼルスカブ Combination therapy for cancer treatment using poxvirus expressing tumor antigen and monoclonal antibody against TIM-3
CN106659777A (en) 2014-06-13 2017-05-10 葛兰素史密丝克莱恩生物有限公司 Immunogenic combinations
KR20190062617A (en) 2014-09-03 2019-06-05 버베리안 노딕 에이/에스 Methods and compositions for enhancing immune responses
WO2016036955A1 (en) 2014-09-03 2016-03-10 Bavarian Nordic A/S Methods and compositions for inducing protective immunity against filovirus infection
EA202092521A1 (en) 2014-09-26 2021-05-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. METHODS AND COMPOSITIONS FOR INDUCTION OF PROTECTIVE IMMUNITY AGAINST INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUS
KR101645642B1 (en) 2014-10-16 2016-08-11 대한민국 Kvac recombinant vaccinia virus derived from kvac strain
KR101623498B1 (en) 2014-10-16 2016-05-24 대한민국 Kvacattenuated vaccinia virus kvac strain
SMT201800602T1 (en) 2014-11-04 2019-01-11 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
AU2016229408A1 (en) 2015-02-25 2017-09-14 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
KR20180006916A (en) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 Use of MVA or MVA delta E3L as an immunotherapeutic agent for solid tumors
AU2016264623B2 (en) 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens
TWI750122B (en) 2015-06-09 2021-12-21 美商博德研究所有限公司 Formulations for neoplasia vaccines and methods of preparing thereof
WO2016202828A1 (en) * 2015-06-15 2016-12-22 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
FR3042121A1 (en) 2015-10-08 2017-04-14 Jean-Marc Limacher ANTI-TUMOR COMPOSITION
CN106591361A (en) * 2015-10-20 2017-04-26 钱文斌 Recombinant pox oncolytic virus, and construction method and application thereof
MA44059B1 (en) 2015-12-15 2019-11-29 Janssen Vaccines & Prevention Bv Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
PL3407910T3 (en) 2016-01-29 2022-08-16 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
CN109152827B (en) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 Recombinant MVA or MVAΔE3L expressing human FLT3L and its use as an immunotherapeutic agent against solid tumors
CA3015650A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
CA3020426A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
CN109922829A (en) 2016-05-02 2019-06-21 扬森疫苗与预防公司 Therapeutic HPV vaccine combination
CN109219448B (en) 2016-06-16 2022-09-20 扬森疫苗与预防公司 HIV vaccine formulations
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
JP2019526580A (en) 2016-09-02 2019-09-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Method for eliciting an immune response against human immunodeficiency virus infection in a subject undergoing antiretroviral treatment
MX2019002938A (en) 2016-09-15 2019-10-15 Janssen Vaccines & Prevention Bv TRIMER STABILIZING MUTATIONS OF HIV ENVELOPE PROTEINS.
CA3036799A1 (en) 2016-09-28 2018-04-05 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
JP7382230B2 (en) 2016-10-17 2023-11-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド Recombinant viral replicon system and its use
US11311613B2 (en) 2016-11-07 2022-04-26 The United States of Americans represented by the Secretary, Department of Health and Human Services Development of agonist epitopes of the human papillomavirus
BR112019011661A2 (en) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
JP2020519666A (en) 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Stable virus-containing composition
AU2018270375B2 (en) 2017-05-15 2025-04-17 Bavarian Nordic A/S Stable virus-containing composition
US11229693B2 (en) 2017-06-15 2022-01-25 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding HIV antigens, and methods of use thereof
AU2018304502B2 (en) 2017-07-19 2022-03-31 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
BR112020003669A2 (en) 2017-08-24 2020-09-01 Bavarian Nordic A/S combination therapy for cancer treatment with intravenous administration of a recombinant mva and an antibody
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
CA3086325A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EP3728291A1 (en) 2017-12-20 2020-10-28 GlaxoSmithKline Biologicals S.A. Epstein-barr virus antigen constructs
BR112020014525A2 (en) 2018-01-19 2020-12-08 Janssen Pharmaceuticals, Inc. INDUCE AND ENHANCE IMMUNE RESPONSES USING RECOMBINANT REPLICON SYSTEMS
US20220001001A1 (en) * 2018-07-13 2022-01-06 University Of Georgia Research Foundation Broadly reactive immunogens of dengue virus, compositions, and methods of use thereof
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
US12252702B2 (en) 2018-09-15 2025-03-18 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
IL281988B2 (en) 2018-10-05 2025-03-01 Bavarian Nordic As Combination therapy for cancer treatment with intravenous administration of recombinant MVA and an immune checkpoint antagonist or agonist
AU2019359204B2 (en) 2018-10-08 2024-12-05 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
EP3880694A1 (en) 2018-11-14 2021-09-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Tp5, a peptide inhibitor of aberrant and hyperactive cdk5/p25 as treatment for cancer
CN113056284A (en) 2018-11-20 2021-06-29 巴法里安诺迪克有限公司 Therapy for treating cancer by intratumoral and/or intravenous administration of recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
TWI852977B (en) 2019-01-10 2024-08-21 美商健生生物科技公司 Prostate neoantigens and their uses
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
BR112021025025A2 (en) 2019-06-11 2022-02-22 Glaxosmithkline Biologicals Sa Mucosal vaccine formulations
BR112022009421A2 (en) 2019-11-14 2022-10-25 Aelix Therapeutics S L DOSAGE SCHEMES FOR VACCINES
BR112022009598A2 (en) 2019-11-18 2022-08-16 Janssen Biotech Inc VACCINES BASED ON MUTANTS CALR AND JAK2 AND USE THEREOF
MX2022005601A (en) 2019-11-20 2022-08-15 Bavarian Nordic As MEDICAL USES OF RECOMBINANT MODIFIED VACCINIA ANKARA (MVA) VIRUS WITH 4-1BB LIGAND (4-1BBL) ADJUVANT.
US20230190922A1 (en) 2019-11-20 2023-06-22 Bavarian Nordic A/S Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
US20230287067A1 (en) 2020-01-21 2023-09-14 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs)
WO2021150713A2 (en) 2020-01-21 2021-07-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunogenic epitopes of h, k, and e human endogenous retroviruses (hervs)
IL296250A (en) 2020-03-12 2022-11-01 Bavarian Nordic As Compositions improving poxvirus stability
JP2023528984A (en) 2020-06-10 2023-07-06 バヴァリアン・ノルディック・アクティーゼルスカブ Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccine Against Coronavirus Disease
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
KR20230050328A (en) 2020-07-08 2023-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 RNA replicon vaccine against HBV
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
WO2023031428A1 (en) 2021-09-03 2023-03-09 Bavarian Nordic A/S Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva)
EP4452305A1 (en) 2021-12-23 2024-10-30 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
EP4452306A1 (en) 2021-12-23 2024-10-30 Bavarian Nordic A/S Therapy for modulating immune response with recombinant mva encoding il-12
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
AU2023298083A1 (en) 2022-06-29 2025-01-09 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
IL317780A (en) 2022-06-29 2025-02-01 Bavarian Nordic As Epstein-barr-virus vaccine
JP2025521488A (en) 2022-06-30 2025-07-10 バヴァリアン・ノルディック・アクティーゼルスカブ Mammalian cell lines for the production of modified vaccinia virus Ankara (MVA)
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2
WO2024188802A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures
WO2024188803A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Production of poxviruses from quail cell cultures
WO2024188801A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Use of quail cell lines for poxvirus production
WO2025120141A1 (en) 2023-12-08 2025-06-12 Bavarian Nordic A/S Downregulation of yield-reducing transgenes expressed by poxvirus

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) * 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
US3914408A (en) * 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
DE2714665A1 (en) * 1977-04-01 1978-10-05 Mayr Anton PREPARATION FOR TREATING HERPES ZOSTER AND OTHER HERPES INFECTIONS AND METHOD FOR THE PRODUCTION THEREOF
US5155020A (en) * 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
GB8322414D0 (en) * 1983-08-19 1983-09-21 Szelke M Renin inhibitors
FR2603040B1 (en) 1986-08-22 1990-01-26 Transgene Sa PROTEIN, DNA SEQUENCE, POXVIRUSES, CELLS AND THEIR CULTURE PROCESS, AS WELL AS THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USEFUL IN THE PREVENTION OF SCHISTOSOMOSIS
AU613583B2 (en) 1986-08-22 1991-08-08 Transgene S.A. Proteins and the method for preparing them, DNA sequences, antibodies and their application, poxviruses, transformed or infected cells, pharmaceutical compositions which are useful in the prevention of schistosomiasis and application by way of an agent possessing glutathione s-transferase activity
DE3743298A1 (en) 1987-12-19 1989-06-29 Wilkinson Sword Gmbh SHAVING APPARATUS AND METHOD FOR PRODUCING A LAYER OF LOW FRICTION RESISTANCE ON A SHAVING APPARATUS
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US6248333B1 (en) * 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
WO1992005246A1 (en) 1990-09-25 1992-04-02 Smithkline Beecham Corporation Medium for culture of mammalian cells
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
DE69233158T2 (en) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville GENETICALLY MANUFACTURED STRAIN FOR VACCINES
US5403582A (en) 1993-01-21 1995-04-04 Nippon Zeon Co., Ltd. Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5490794A (en) * 1993-11-05 1996-02-13 Sumitomo Wiring Systems, Ltd. Branch joint box
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (en) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotent non-specific immunity inducers based on combinations of poxvirus components, processes for their preparation and their use as pharmaceuticals
ATE298370T1 (en) * 1994-04-29 2005-07-15 Baxter Healthcare Sa RECOMBINANT POXVIRUSES WITH FOREIGN POLYNUCLEOTES IN IMPORTANT REGIONS
WO1996003144A1 (en) * 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
US5676950A (en) * 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5753489A (en) 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5566011A (en) * 1994-12-08 1996-10-15 Luncent Technologies Inc. Antiflector black matrix having successively a chromium oxide layer, a molybdenum layer and a second chromium oxide layer
UA68327C2 (en) † 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
WO1997031119A1 (en) 1996-02-21 1997-08-28 Res Inst For Genetic And Human Methods and compositions for protective and therapeutic genetic immunization
WO1998004680A1 (en) 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
WO1998013500A2 (en) † 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AU5091898A (en) 1996-10-25 1998-05-15 Wistar Institute Of Anatomy And Biology, The Method of vaccinating infants against infections
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
DE19729279A1 (en) † 1997-07-09 1999-01-14 Peter Hildebrandt Urological implant, in particular vascular wall support for the urinal tract
WO1999007869A1 (en) † 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
DE69839970D1 (en) 1998-11-10 2008-10-16 Univ Rochester METHODS FOR GENBAN PRODUCTION
GB2370571B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd A modified 5t4 antigen
AU766954B2 (en) 1998-11-18 2003-10-30 Oxford Biomedica (Uk) Limited Polypeptide
US6173813B1 (en) 1998-12-23 2001-01-16 Otis Elevator Company Electronic control for an elevator braking system
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US20020106798A1 (en) * 2000-03-02 2002-08-08 Robinson Harriet L. DNA expression vectors and methods of use
KR100880765B1 (en) 2000-03-14 2009-02-02 버베리안 노딕 에이/에스 Modified strains of modified vaccinia virus Ankara (ＭＶＡ)
KR100341030B1 (en) 2000-03-16 2002-06-20 유태욱 method for replaying caption data and audio data and a display device using the same
KR20030036194A (en) 2000-05-24 2003-05-09 메리알 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant poxvirus vaccine
HK1054329B (en) * 2000-07-11 2005-10-07 Aicuris Gmbh & Co. Kg Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU3163902A (en) 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
UA82466C2 (en) * 2001-07-18 2008-04-25 Бавариан Нордика А/С Method for intensification of chordopoxvirus amplification
CN101397574A (en) * 2001-12-04 2009-04-01 巴法里安诺迪克有限公司 Flavivirus NS1 subunit vaccine
ES2247404T3 (en) 2001-12-20 2006-03-01 Bavarian Nordic A/S METHOD FOR THE RECOVERY AND PURIFICATION OF POXVIRUS OF INFECTED CELLS.
AU2003219057A1 (en) 2002-03-15 2003-09-29 Baxter Healthcare S.A. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
JP4801880B2 (en) * 2002-04-19 2011-10-26 バヴァリアン・ノルディック・アクティーゼルスカブ Mutant vaccinia virus Ankara for newborn immunization
KR101138067B1 (en) * 2002-05-16 2012-04-24 버베리안 노딕 에이/에스 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
BR0310020A (en) * 2002-05-16 2005-02-15 Bavarian Nordic As Expression of genes in modified vaccinia virus ankara by use of vaccinia ati promoter
KR101044538B1 (en) * 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 Primary cell culture and virus propagation under serum-free conditions
EA012723B1 (en) * 2002-11-25 2009-12-30 Бавариан Нордик А/С Recombinant poxvirus comprising at least two cowpox ati promoters
US6976752B2 (en) * 2003-10-28 2005-12-20 Lexmark International, Inc. Ink jet printer with resistance compensation circuit
DE602004009743T2 (en) * 2003-11-24 2008-08-28 Bavarian Nordic A/S Promoters for expression in modified vaccinia virus Ankara
EP1586330A1 (en) * 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
US8354093B2 (en) * 2004-10-15 2013-01-15 Washington University Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US7807146B2 (en) * 2006-10-06 2010-10-05 Bn Immunotherapeutics, Inc. Methods for treating cancer with a recombinant MVA expressing HER-2
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8268327B2 (en) * 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
ES2608604T3 (en) * 2007-10-18 2017-04-12 Bavarian Nordic A/S Use of MVA to treat prostate cancer

Similar Documents

Publication Publication Date Title
RU2003118436A (en) ANKARA MODIFIED VERSION OF ANKARA
RU2280075C2 (en) Alternated strain of modified vaccinia virus ankara (mva)
JP2926270B2 (en) Pharmaceutical composition for prevention and treatment of papillomavirus-induced tumors
UA75411C2 (en) Recombinant virus of mva
JP5166505B2 (en) Recombinant MVA and production method thereof
JPH025860A (en) Recombinant vaccinia virus MVA
JP2002348255A (en) Immunization method with recombinant avipoxvirus
EP1420822A2 (en) Modified vaccinia virus ankara for the vaccination of neonates
CN101142319B (en) Vaccines based on the use of modified Ankara vaccinia virus
CN1842602A (en) Modified Ankara vaccinia virus (MVA) mutants and uses thereof
WO2022071513A1 (en) IMPROVED DNA VACCINE FOR SARS-CoV-2
ES2424847T3 (en) Foot and mouth disease virus genes expressing recombinant avipox
DE10144664A1 (en) Vaccinia virus MVA-E3L knock-out mutants and use thereof
CN109536529A (en) A kind of efficient vaccinia virus recombinant carrier and its method for building up
CA2223419A1 (en) Recombinant poxvirus-calicivirus [rabbit hemorrhagic disease virus (rhdv)] compositions and uses
JP2000502900A (en) Recombinant virus pseudoparticles and their vaccines and antitumor uses
JPH10512151A (en) Immunogenic compositions containing recombinant attenuated poxvirus expressing HTLV antigen
US20110064769A1 (en) Vv promoter-driven overexpression of recombinant antigens
RU2588388C1 (en) Recombinant strain l-ivp 1421abjcn pox virus virulence genes with broken a56r, b8r, j2r, c3l, n1l for producing live culture of attenuated smallpox vaccine and other orthopoxviruses, pathogenic for humans
RIAZANKIN et al. Recombinant Strain of Vaccinia Virus Capable of Producing a Chimeric Protein TBI-Hbs Ag
WO1998015635A2 (en) Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine